Signs, Symptoms, and When to Seek Urgent Care
At a Glance
Pancreatic cancer can cause jaundice, unexplained weight loss, oily stools, new diabetes, and upper abdominal or back pain. Fever during chemotherapy, jaundice with fever or confusion, repeated vomiting, blood clot symptoms, severe bleeding, or uncontrolled pain require urgent evaluation.
The symptoms of pancreatic cancer are notoriously “quiet” in the early stages, often mimicking common digestive issues like indigestion or gallstones [1]. This subtle start is why many people are not diagnosed until the cancer has progressed. Recognizing these signs—and knowing when they transition from “concerning” to “emergency”—is a vital part of managing your care.
Common and Overlooked Symptoms
Because the pancreas sits deep in the abdomen, tumors can grow for some time before they press on nerves or block ducts.
- Painless Jaundice: This is one of the most classic signs. You may notice yellowing of the skin or the whites of the eyes (jaundice), dark tea-colored urine, or pale, clay-colored stools [1]. When this happens without significant abdominal pain, it often points toward a blockage in the bile duct caused by a tumor in the “head” of the pancreas [2].
- Weight Loss and Digestive Changes: Rapid, unexplained weight loss and a loss of appetite are common [1]. You may also notice steatorrhea—oily, foul-smelling stools that float—which happens when the cancer prevents the pancreas from releasing the enzymes needed to digest fat [3].
- New-Onset Diabetes: While diabetes is very common in the general population, new-onset diabetes in someone over age 50—especially when accompanied by weight loss and lacking a family history—can occasionally be an early sign of pancreatic issues and may warrant investigation [4][5][6].
- Abdominal or Back Pain: This pain often starts in the upper abdomen and may “radiate” or spread to the middle of your back [1]. It may feel worse after eating or when lying down.
Understanding the CA 19-9 Marker
CA 19-9 is a protein (a tumor marker) often found in the blood of people with pancreatic cancer. While helpful, it has significant limitations that you should discuss with your team.
- The “Non-Secretors”: About 5% to 10% of the population are Lewis-antigen negative. Their bodies cannot produce CA 19-9, so their levels may remain zero or very low even if a tumor is growing [7][8].
- False Positives from Blockage: If your bile duct is blocked or your gallbladder is inflamed, your CA 19-9 can skyrocket (sometimes into the thousands) even without cancer [9][10]. Doctors should wait until a bile duct stent is placed and your jaundice improves before using CA 19-9 as a reliable “baseline” [11].
- Trend Over Time: A single CA 19-9 number is less important than the trend. There is no universal percentage drop that guarantees success; instead, the trend is interpreted alongside your clinical picture and imaging [12]. CEA and CA-125 are sometimes tested but are not fully validated routine substitutes for CA 19-9 [13].
When to Seek Emergency Care
While many symptoms can be managed during a scheduled office visit, some complications require immediate medical intervention in an emergency room.
Immediate Emergencies (Go to the ER or call your clinical emergency line)
- Chemotherapy Fever (Neutropenic Fever): If you are receiving chemotherapy and develop a fever (often defined as around 100.4°F/38.0°C or higher, depending on your team’s exact instruction), you must contact your oncology team immediately or go to the ER, even if you do not have jaundice. This can signal a life-threatening infection.
- Signs of Cholangitis: If you have jaundice (yellow skin/eyes) combined with a fever, chills, or confusion, you may have a life-threatening infection of the bile ducts called cholangitis [14].
- Gastric Outlet Obstruction: If you are vomiting repeatedly, cannot keep down any liquids or medications, or have a severely bloated and painful abdomen, the tumor may be physically blocking the exit of your stomach [15][16].
- Blood Clots (VTE): Pancreatic cancer significantly increases your risk of blood clots [17]. Seek emergency care for:
- DVT: Sudden swelling, pain, or redness in one leg.
- Pulmonary Embolism: Sudden shortness of breath, chest pain that worsens with a deep breath, or coughing up blood.
- Severe Bleeding: Vomiting blood (which may look like coffee grounds) or passing black, tarry, or bloody stools [18].
- Uncontrolled Pain: Pain that is so severe you cannot rest, eat, or move, and does not respond to your prescribed “breakthrough” pain medications [19].
Urgent Concerns (Call your care team for a same-day or next-day visit)
- New Jaundice: If you notice your eyes turning yellow but you have no fever or severe pain, contact your clinic the same day.
- Significant Nausea: If you are struggling to eat but can still keep down some fluids and medications.
- New Weakness: Feeling significantly more dizzy or faint than usual, which may indicate dehydration or anemia.
- Breakthrough Pain: If your current pain regimen is no longer keeping you comfortable, your team needs to adjust your dose or “rotation” of medications [20].
Common questions in this guide
What symptoms can pancreatic cancer cause early on?
When is jaundice with pancreatic cancer an emergency?
Can a CA 19-9 blood test rule out pancreatic cancer?
What fever should I report during pancreatic cancer chemotherapy?
What blood clot symptoms require emergency care with pancreatic cancer?
When does vomiting or pain from pancreatic cancer need the ER?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Am I 'Lewis-antigen negative,' and if so, how should we monitor my cancer markers since CA 19-9 may not be accurate?
- 2.If my CA 19-9 was high when I was jaundiced, should we re-test it now that my bile duct has been drained?
- 3.I have new-onset diabetes; how does this change my nutritional needs or the way we monitor my cancer?
- 4.What is the 'after-hours' plan if I develop a fever or can't stop vomiting? Which hospital should I go to?
- 5.How can I distinguish between normal treatment-related fatigue and a more serious complication like a blood clot?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (20)
- 1
Early detection of sporadic pancreatic cancer: time for change.
Frič P, Šedo A, Škrha J, et al.
European journal of gastroenterology & hepatology 2017; (29(8)):885-891 doi:10.1097/MEG.0000000000000904.
PMID: 28471824 - 2
The connection between innervation and metabolic rearrangements in pancreatic cancer through serine.
Dong M, Cao L, Cui R, Xie Y
Frontiers in oncology 2022; (12()):992927 doi:10.3389/fonc.2022.992927.
PMID: 36582785 - 3
Approach to the Patient with Pancreatogenic Diabetes.
Ode KL, Imai Y, Norris AW
The Journal of clinical endocrinology and metabolism 2025; doi:10.1210/clinem/dgaf623.
PMID: 41252284 - 4
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes.
Boursi B, Finkelman B, Giantonio BJ, et al.
Gastroenterology 2017; (152(4)):840-850.e3 doi:10.1053/j.gastro.2016.11.046.
PMID: 27923728 - 5
Treatment of type 2 diabetes mellitus and risk of pancreatic cancer.
Olakowska E, Olakowski M
Endokrynologia Polska 2021; (72(4)):395-401 doi:10.5603/EP.a2021.0069.
PMID: 34410681 - 6
Risk Factors for Pancreatic Cancer in Patients with New-Onset Diabetes: A Systematic Review and Meta-Analysis.
Mellenthin C, Balaban VD, Dugic A, Cullati S
Cancers 2022; (14(19)) doi:10.3390/cancers14194684.
PMID: 36230607 - 7
New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Luo G, Fan Z, Cheng H, et al.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2018; (18(8)):971-976 doi:10.1016/j.pan.2018.08.003.
PMID: 30131287 - 8
Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency.
Parra-Robert M, Santos VM, Canis SM, et al.
Anticancer research 2018; (38(10)):5883-5888 doi:10.21873/anticanres.12931.
PMID: 30275214 - 9
Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS, Jeon TJ, Park JY, et al.
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2017; (70(2)):96-102 doi:10.4166/kjg.2017.70.2.96.
PMID: 28830135 - 10
Dilemma of elevated CA 19-9 in biliary pathology.
Tsen A, Barbara M, Rosenkranz L
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2018; (18(8)):862-867 doi:10.1016/j.pan.2018.09.004.
PMID: 30249386 - 11
Acute Cholecystitis with Significantly Elevated Levels of Serum Carbohydrate Antigen 19-9.
Akimoto S, Banshodani M, Nishihara M, et al.
Case reports in gastroenterology 2016; (10(2)):410-416 doi:10.1159/000448068.
PMID: 27721726 - 12
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Chung KH, Ryu JK, Lee BS, et al.
Journal of gastroenterology and hepatology 2016; (31(2)):506-12 doi:10.1111/jgh.13075.
PMID: 26250642 - 13
Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Luo G, Liu C, Guo M, et al.
Annals of surgery 2017; (265(4)):800-805 doi:10.1097/SLA.0000000000001741.
PMID: 28267695 - 14
Clinical Outcomes and Complications of Endoscopic Biliary Stenting for Malignant Distal Biliary Obstruction in Pancreatic Cancer: A Systematic Review.
Abdiyev N, Jaxymbayev N, Maira M, et al.
Journal of clinical medicine 2026; (15(8)) doi:10.3390/jcm15083126.
PMID: 42074927 - 15
Palliative Stenting for Gastric Outlet Obstruction Secondary to Pancreatic Adenocarcinoma.
Patel D, Bhullar FA, Tagliaferri AR, et al.
Cureus 2024; (16(1)):e53186 doi:10.7759/cureus.53186.
PMID: 38425636 - 16
Gastric Perforation: A Rare Presentation of Malignant Gastric Outlet Obstruction.
Silangruz K, Shah P, Fujii-Lau L, Furuta S
Cureus 2022; (14(2)):e22242 doi:10.7759/cureus.22242.
PMID: 35340499 - 17
Burden of venous thromboembolism in patients with pancreatic cancer.
Frere C
World journal of gastroenterology 2021; (27(19)):2325-2340 doi:10.3748/wjg.v27.i19.2325.
PMID: 34040325 - 18
Characteristics of gastrointestinal hemorrhage associated with pancreatic cancer: A retrospective review of 246 cases.
Wang YU, Yuan C, Liu X
Molecular and clinical oncology 2015; (3(4)):902-908 doi:10.3892/mco.2015.563.
PMID: 26171204 - 19
Endoscopic ultrasonography-guided celiac plexus neurolysis in patients with unresectable pancreatic cancer: An update.
Pérez-Aguado G, de la Mata DM, Valenciano CM, Sainz IF
World journal of gastrointestinal endoscopy 2021; (13(10)):460-472 doi:10.4253/wjge.v13.i10.460.
PMID: 34733407 - 20
Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients.
Zschaeck S, Blümke B, Wust P, et al.
PloS one 2017; (12(10)):e0186341 doi:10.1371/journal.pone.0186341.
PMID: 29023527
This page explains pancreatic cancer symptoms, CA 19-9 limitations, and urgent warning signs for informational purposes only and does not constitute medical advice. Contact your oncology team or emergency services for symptoms described as emergencies.
Get notified when new evidence is published on exocrine pancreatic carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.